QUANTIFYING AXIAL ROTATION OF UPPER EXTREMITY SEGMENTS

The calibrated anatomical systems technique (CAST) (Cappozzo et al, 1995) is an established method in gait and lower limb analyses. Its application to 6-degrees-of-freedom kinematic analyses and reduction of soft tissue artefact could make it particularly useful in quantifying axial rotation of the upper extremity. Such rotations have been established as being important in generating racket-head velocity in a variety of racket skills (Marshall and Elliott, 2000). The present study assesses the accuracy of CAST in quantifying the rotation of the forearm

A lower limit of 50 microgauss for the magnetic field near the Galactic Centre

The amplitude of the magnetic field near the Galactic Centre has been uncertain by two orders of magnitude for several decades. On a scale of ~100 parsecs (pc), fields of ~1,000 microgauss (μG; refs 1–3) have been reported, implying a magnetic energy density more than 10,000 times stronger than typical for the Galaxy. Alternatively, the assumption of pressure equilibrium between the various phases of the Galactic Centre interstellar medium (including turbulent molecular gas, the contested^4 ‘very hot’ plasma, and the magnetic field) suggests fields of ~100 μG over ~400 pc size scales^5. Finally, assuming equipartition, fields of only ~6 μG have been inferred from radio observations^6 for 400 pc scales. Here we report a compilation of previous data that reveals a downward break in the region's non-thermal radio spectrum (attributable to a transition from bremsstrahlung to synchrotron cooling of the in situ cosmic-ray electron population). We show that the spectral break requires that the Galactic Centre field be at least ~50 μG on 400 pc scales, lest the synchrotron-emitting electrons produce too much γ-ray emission, given other existing constraints^7. Other considerations support a field of 100 μG, implying that over 10% of the Galaxy's magnetic energy is contained in only ≲0.05% of its volume

Social networks, work and network-based resources for the management of long-term conditions: a framework and study protocol for developing self-care support

Background: increasing the effective targeting and promotion of self-care support for long-term conditions requires more of a focus on patient contexts and networks. The aim of this paper is to describe how within a programme of research and implementation, social networks are viewed as being centrally involved in the mobilisation and deployment of resources in the management of a chronic condition. This forms the basis of a novel approach to understanding, designing, and implementing new forms of self-management support.Methods: drawing on evidence syntheses about social networks and capital and the role of information in self-management, we build on four conceptual approaches to inform the design of our research on the implementation of self-care support for people with long-term conditions. Our approach takes into consideration the form and content of social networks, notions of chronic illness work, normalisation process theory (NPT), and the whole systems informing self-management engagement (WISE) approach to self-care support.Discussion: the translation and implementation of a self-care agenda in contemporary health and social context needs to acknowledge and incorporate the resources and networks operating in patients' domestic and social environments and everyday lives. The latter compliments the focus on healthcare settings for developing and delivering self-care support by viewing communities and networks, as well as people suffering from long-term conditions, as a key means of support for managing long-term conditions. By focusing on patient work and social-network provision, our aim is to open up a second frontier in implementation research, to translate knowledge into better chronic illness management, and to shift the emphasis towards support that takes place outside formal health services.<br/

Australia Telescope Compact Array Radio Continuum 1384 and 2368 Mhz Observations of Sagittarius B

We present images of the Sagittarius (Sgr) B giant molecular cloud at 2368 and 1384 MHz obtained using new, multi-configuration Australia Telescope Compact Array (ATCA) observations. We have combined these observations with archival single-dish observations yielding images at resolutions of 47" by 14" and 27" by 8" at 1384 and 2368 MHz respectively. These observations were motivated by our theoretical work (Protheroe et al. 2008) indicating the possibility that synchrotron emission from secondary electrons and positrons created in hadronic cosmic ray (CR) collisions with the ambient matter of the Sgr B2 cloud could provide a detectable (and possibly linearly polarized) non-thermal radio signal. We find that the only detectable non-thermal emission from the Sgr B region is from a strong source to the south of Sgr B2, which we label Sgr B2 Southern Complex (SC). We find Sgr B2(SC) integrated flux densities of 1.2+/-0.2 Jy at 1384 MHz and 0.7+/-0.1 Jy at 2368 MHz for a source of FWHM size at 1384 MHz of ~54". Despite its non-thermal nature, the synchrotron emission from this source is unlikely to be dominantly due to secondary electrons and positrons. We use polarization data to place 5-sigma upper limits on the level of polarized intensity from the Sgr B2 cloud of 3.5 and 3 mJy/beam at 1384 and 2368 MHz respectively. We also use the angular distribution of the total intensity of archival 330 MHz VLA and the total intensity and polarized emission of our new 1384 MHz and 2368 MHz data to constrain the diffusion coefficient for transport of the parent hadronic CRs into the dense core of Sgr B2 to be no larger than about 1% of that in the Galactic disk. Finally, we have also used the data to perform a spectral and morphological study of the features of the Sgr B cloud and compare and contrast these to previous studies.Comment: 7 pages, 4 figures, matches version published in the Astronomical Journa

Interaction of detergents and disinfectants upon surface adhered populations of Escherichia coli and Listeria monocytogenes

The primary aim of this investigation was to identify and assess the interactions (synergies and antagonisms) that exist between 20 minute detergent and 5 minute disinfectant treatments upon three factory isolated strains of surface adhered (1-hour attached) and surface adapted (24-hour biofilm) populations of Escherichia coli and Listeria monocytogenes, plus a comparison with vero-toxin producing strains of E. coli, when used as part of a cleaning and disinfection regime. The detergents chosen for assessment were two non-ionic (91/4 - Alcohol Ethoxylate and KCL5 - Polyethoxylated Alcohol), two anionic (LX28 - Sodium Lauryl Sulphate and Nec28 - Sodium Laurylether Sulphate) and two novel bismuth thiols (BisEDT - 1:1 Bismuth nitrate 1,2-ethanedithiol and BisTOL - 2:1 Bismuth nitrate 3,4-dimercaptotoluene), developed at Winthrop University Hospital, New York. The disinfectants chosen for assessment were a quaternary ammonium compound (BAC - Benzyl alkonium Chloride) and a chlorine releasing agent (NaDCC - Sodium Dichloroisocyanurate). The investigation showed that there were no specific cleaning and disinfection regimes that will adequately target both E. coli and L. monocytogenes strains. It was also concluded that to maximise the removal and disinfection of persistent strains of a given microorganism, it may be necessary to design a regime to specifically target not just the species, but the strain involved and where possible requires mechanical cleaning. The novel bismuth thiols were seen to be promising detergents to aid in the removal of E. coli strains and warrant further attention for future studies. Finally, an investigation to identify possible mechanisms of resistance to disinfectant treatments following detergent treatment, showed that different detergents can induce expression of the stress response proteins, HSP60 and HSP70, at differing levels of expression after the same contact time and against different states of adherent populations, i.e. 1-hour attached or 24-hour biofilm populations.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

TeV Astrophysics Constraints on Planck Scale Lorentz Violation

We analyze observational constraints from TeV astrophysics on Lorentz violating nonlinear dispersion for photons and electrons without assuming any a priori equality between the photon and electron parameters. The constraints arise from thresholds for vacuum Cerenkov radiation, photon decay and photo-production of electron-positron pairs. We show that the parameter plane for cubic momentum terms in the dispersion relations is constrained to an order unity region in Planck units. We find that the threshold configuration can occur with an asymmetric distribution of momentum for pair creation, and with a hard photon for vacuum Cerenkov radiation.Comment: 4 pages, RevTeX4, 1 figure. Some references and a footnote added, improved discussion on the photon annihilation and GZK cutoff. Minor changes of wording. Main results unchanged. Version to appear as a Rapid Communication in PR

Genomic evolution and transcriptional changes in the evolution of prostate cancer into neuroendocrine and ductal carcinoma types

Prostate cancer is typically of acinar adenocarcinoma type but can occasionally present as neuroendocrine and/or ductal type carcinoma. These are associated with clinically aggressive disease, and the former often arises on a background of androgen deprivation therapy, although it can also arise de novo. Two prostate cancer cases were sequenced by exome capture from archival tissue. Case 1 was de novo small cell neuroendocrine carcinoma and ductal adenocarcinoma with three longitudinal samples over 5 years. Case 2 was a single time point after the development of treatment-related neuroendocrine prostate carcinoma. Case 1 showed whole genome doubling in all samples and focal amplification of AR in all samples except the first time point. Phylogenetic analysis revealed a common ancestry for ductal and small cell carcinoma. Case 2 showed 13q loss (involving RB1) in both adenocarcinoma and small cell carcinoma regions, and 3p gain, 4p loss, and 17p loss (involving TP53) in the latter. By using highly curated samples, we demonstrate for the first time that small-cell neuroendocrine and ductal prostatic carcinoma can have a common ancestry. We highlight whole genome doubling in a patient with prostate cancer relapse, reinforcing its poor prognostic nature

ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin.

Background: gemcitabine (G) and cisplatin (C) is a standard-of-care, combination chemotherapy regimen for neoadjuvant treatment of muscle-invasive and palliative treatment of advanced bladder cancer (BC). More effective regimens are urgently needed, with no significant improvements on GC in more than a decade. Mammalian target of rapamycin (mTOR) is a rational target for BC therapy, as abnormalities are commonly seen in mTOR’s upstream activators/downstream effectors in the PI3K/AKT/mTOR signaling pathway. We therefore performed a Phase Ib trial, combining escalating doses of the mTOR inhibitor, temsirolimus (T) with GC. Methods: following regulatory and ethical approvals, eligible patients with advanced malignancy were treated with one or more doses of intravenous (IV) T plus fixed doses of IV GC in a 21-day (d) cycle. Previous unpublished data suggest a possible interaction between G and T. We therefore pursued a cautious escalation strategy (see table), as a precaution against excessive toxicity. Results: 14 patients (3 BC, 2 lung, 2 ovarian, 7 other cancers; 7 previous platinum exposure) were treated, at 4 dose schedules in 2 UK centers. There were no treatment-related deaths or SUSARs. Of 14 SAEs, 4 were SARs, in 10 individuals, 7 of whom had received IMP. Addition of 10mg T on d15, then d8&15 was tolerated, but DLTs were encountered when administering three 10mg doses of T, both on d1,8&15 (neutropenia; hypokalaemia) and d2,9&15 (febrile neutropenia; rash). T was omitted because of myelosuppression on d15, cycle 1 in 6/8 patients scheduled to receive 3 doses of T. Conclusions: it has not been feasible to add three, weekly doses of T to GC, even at low T doses, in the patient group tested, because of predominantly hematological toxicity. We plan to amend the schedule to include two doses of T, on d2&9, informed by data from pre-planned PK analyses of patients already treated. ToTem was developed by the UK NCRI Bladder Cancer Clinical Studies Group, sponsored by Cardiff University, funded by Cancer Research UK, and supported by supply of free drug and distribution costs from Pfizer. Clinical trial information: 31546330

The cosmic ray distribution in Sagittarius B

Copyright © 2007. The American Astronomical Society. All rights reserved. Printed in U.S.A. Submitted to Cornell University’s online archive www.arXiv.org in 2007 by Roland M. Crocker. Post-print sourced from www.arxiv.orgThe H.E.S.S. instrument has observed a diffuse flux of ∼TeV γ-rays from a large solid angle around the Galactic center (GC). This emission is correlated with the distribution of gas in the region, suggesting that the γ-rays originate in collisions between cosmic-ray hadrons (CRHs) and ambient matter. Of particular interest, H.E.S.S. has detected γ-rays from the Sagittarius (Sgr) B molecular cloud complex. Prompted by the suggestion of a hadronic origin for the γ-rays, we have examined archival 330 and 74 MHz Very Large Array radio data and 843 MHz Sydney University Molonglo Sky Survey data covering Sgr B, looking for synchrotron emission from secondary electrons and positrons (expected to be created in the same interactions that supply the observed γ-rays). Intriguingly, we have uncovered nonthermal emission, but at a level exceeding expectation. Adding to the overall picture, recent observations by the Atacama Pathfinder Experiment telescope show that the cosmic-ray ionization rate is 10 times greater in the Sgr B2 region of Sgr B than the local value. Lastly, Sgr B2 is also a very bright X-ray source. We examine scenarios for the spectra of CRHs and/or primary electrons that would reconcile all these different data. We determine that (1) a hard (∼E -2.2), high-energy (≳TeV) population of CRHs is unavoidably required by the H.E.S.S. γ-ray data, and (2) the remaining broadband, nonthermal phenomenology is explained either by a rather steep (∼E -2.9) spectrum of primary electrons or a (∼E-2.7) population of CRHs. Perhaps unsurprisingly, no single power-law population of either leptons or hadrons can explain the totality of broadband, nonthermal Sgr B phenomenology. © 2007. The American Astronomical Society. All rights reserved.Roland M. Crocker, David Jones, Raymond J. Protheroe, Jürgen Ott, Ron Ekers, Fulvio Melia, Todor Stanev, and Anne Gree

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome : A 24-Week, Phase III Study

Background This study evaluated the safety and efficacy of teduglutide in pediatric patients with short bowel syndrome-associated intestinal failure (SBS-IF). Methods A 24-week, phase III trial with 2 randomized, double-blind teduglutide dose groups and a nonblinded standard of care (SOC) arm was used; patients received 0.025 mg/kg or 0.05 mg/kg teduglutide once daily. Safety end points included treatment-emergent adverse events (TEAEs) and growth parameters. The primary efficacy/pharmacodynamic end point was the number of patients who achieved a >= 20% reduction in parenteral support (PS) from baseline at week 24. Results All 59 enrolled patients completed the study (0.025 mg/kg, n = 24; 0.05 mg/kg, n = 26; SOC, n = 9). Baseline demographics and disease characteristics were comparable among groups. TEAEs were reported by 98% and 100% of patients in the teduglutide and SOC groups, respectively. The most common TEAEs in the teduglutide-treated groups were pyrexia and vomiting. The primary end point was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg teduglutide, and SOC, respectively (P <0.05 vs SOC). Both 0.025-mg/kg and 0.05-mg/kg teduglutide groups showed clinically significant reductions in PS volume (P <0.05 vs SOC), PS calories, days per week and hours per day of PS infusions, and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline. Two (8.3%, 0.025 mg/kg teduglutide) and 3 patients (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. Conclusion The safety profile of teduglutide was similar to that reported previously in children and adults. Treatment with teduglutide was associated with significant reductions in PS for pediatric patients with SBS-IF over 24 weeks.Peer reviewe